上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Liproxstatin-1 纯度: 98.32%
Liproxstatin-1 是一种有效的 ferroptosis 抑制剂,抑制 ferroptotic 细胞死亡 (IC50=22 nM)。
Liproxstatin-1 Chemical Structure
CAS No. : 950455-15-9
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1406 | In-stock | |
2 mg | ¥750 | In-stock | |
5 mg | ¥1100 | In-stock | |
10 mg | ¥1800 | In-stock | |
50 mg | ¥6600 | In-stock | |
100 mg | ¥8100 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Liproxstatin-1 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Anti-Cancer Compound Library
- CNS-Penetrant Compound Library
- Ferroptosis Compound Library
生物活性 |
Liproxstatin-1 is a potent ferroptosis inhibitor and inhibits ferroptotic cell death (IC50=22 nM)[1]. |
IC50 & Target |
IC50: 22 nM (ferroptosis)[2] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Liproxstatin-1 shows antiferroptotic activity with an IC50 of approximately 38 nM in mouse embryonic fibroblasts[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
Liproxstatin-1 (10 mg/kg, i.p.) suppresses ferroptosis in human cells, Gpx4−/− kidney and in an ischaemia/reperfusion-induced tissue injury model[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
340.85 |
||||||||||||||||
Formula |
C19H21ClN4 |
||||||||||||||||
CAS 号 |
950455-15-9 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 31 mg/mL (90.95 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
To induce the knockout of Gpx4, cells are seeded onto 96-well plates (1,000 cells per well) and treated with 1 μM 4-OH-ICI 47699 (TAM) after plating. Cell viability is assessed at different time points after treatment (usually 72 h) using AquaBluer, unless stated otherwise, as an indicator of viable cells. Alternatively, cell death is also quantified by measuring released lactate dehydrogenase (LDH) activity using the Cytotoxicity Detection Kit. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [1] |
Animals includes in the treatment study of inducible Gpx4−/− mice are equally distributed between sex and weight, with typically 8-10 weeks of age. The average weight within the groups is between 22 and 24 g. Groups are formed to have comparable numbers of females/males of the same age. Animal weight is arranged to have a similar distribution between females and males. For the pharmacological inhibitor experiments, CreERT2;Gpx4fl/fl mice are injected on day 1 and 3 with 0.5 mg TAM dissolved in Miglyol. On day 4, compound treatment is started (Liproxstatin-1: 10 mg/kg) along with vehicle control (1% dimethylsulphoxide (DMSO) in PBS). Liproxstatin-1 and vehicle control are administered once daily by i.p. injection. Survival analysis is performed using the GraphPad Prism software and statistical analysis is done according to the log-rank test. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务